When AI designs a drug, who gets the credit?

Insilico Medicine announced that its generative AI platform identified a promising molecule for pulmonary fibrosis, stating the drug was “discovered by” the AI. The claim highlights a growing trend of biotech firms using AI to generate novel drug candidates that may be beyond human intuition, and prompts discussion about credit for AI‑driven discoveries.

Summary written by Kernelia from the original article by MIT Technology Review. The story and its rights belong to its author.